PRAX logo

Praxis Precision Medicines Inc. (PRAX)

$305.06

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on PRAX

Market cap

$8.53B

EPS

-12.82

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

2.874881

Price on PRAX

Previous close

$310.27

Today's open

$315.74

Day's range

$300.99 - $319

52 week range

$160.11 - $392.70

Profile about PRAX

CEO

Marcio Souza

Employees

168

Headquarters

Boston, MA

Exchange

Nasdaq Global Select

Shares outstanding

27951553

Issue type

Common Stock

PRAX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on PRAX

Praxis Precision Medicines, Inc. (PRAX) Presents at UBS Global Biopharma Conference 2026 Transcript

Praxis Precision Medicines, Inc. ( PRAX ) UBS Global Biopharma Conference 2026 November 16, 2026 5:40 AM EST Company Participants Marcio Souza - President, CEO & Director Conference Call Participants Joon Lee - UBS Investment Bank, Research Division Presentation Joon Lee UBS Investment Bank, Research Division Okay. Well, thank you, everyone, for joining us for this inaugural UBS Global Biopharma Conference.

news source

Seeking Alpha • Nov 16, 2026

news preview

Praxis Precision Medicines: No Material Changes After Q3 And Investor Day (Rating Kept)

I maintain a Strong Buy on Praxis Precision Medicines, with a $601 fair value, 85% above the November 12 close. The valuation falls from $664 primarily after correcting the share count for pre-funded warrants and options; lower net cash also reduces value. Ulixacaltamide is the principal risk: its January FDA decision moves modeled value to $679 on approval or $159 on a complete response letter.

news source

Seeking Alpha • Nov 16, 2026

news preview

Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day

Detailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of December 27, 2026 and January 29, 2027

news source

GlobeNewsWire • Nov 12, 2026

news preview

Praxis Precision Medicines, Inc. (PRAX) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

Praxis Precision Medicines, Inc. ( PRAX ) 3rd Annual Guggenheim Healthcare Innovation Conference November 9, 2026 9:30 AM EST Company Participants Marcio Souza - President, CEO & Director Tim Kelly - CFO & Treasurer Conference Call Participants Yatin Suneja - Guggenheim Securities, LLC, Research Division Presentation Yatin Suneja Guggenheim Securities, LLC, Research Division All right. I think we're live now.

news source

Seeking Alpha • Nov 11, 2026

news preview

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results

FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing Topline results from the EMERALD study of relutrigine in broad developmental and epileptic encephalopathies (DEEs) expected in the fourth quarter of 2026 Cash and investments of approximately $1.3 billion as of September 30, 2026 maintain runway into 2028 Praxis to host an in-person and virtual Investor Day on November 12, 2026 and will participate in a fireside chat at the Guggenheim Biotech Summit today, November 9 at 9:30am ( register here ) BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today provided a corporate update and reported financial results for the third quarter of 2026. “We are entering a defining period for Praxis, with two key regulatory milestones ahead and the opportunity to become a commercial CNS company.

news source

GlobeNewsWire • Nov 9, 2026

news preview

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on November 2, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 23,219 shares of its common stock to fifty-nine new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

news source

GlobeNewsWire • Nov 4, 2026

news preview

Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation

BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report financial results for the third quarter ended September 30, 2026, before the financial markets open on Monday, November 9, 2026. The Company also announced details of its upcoming Investor Day and participation in November investor conferences.

news source

GlobeNewsWire • Oct 27, 2026

news preview

Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)

Praxis Precision Medicines has surged over 1,000% since April 2025, driven by pivotal clinical wins for ulixacaltamide and relutrigine. Ulixacaltamide and relutrigine, both with 2026–2027 PDUFA dates, target large, underserved CNS markets with combined peak sales potential exceeding $15 billion. PRAX's $1.4 billion cash position supports a commercial buildout and reduces near-term capital market risk, with further upside from potential out-licensing and priority review vouchers.

news source

Seeking Alpha • Sep 12, 2026

news preview

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.

news source

Zacks Investment Research • Aug 11, 2026

news preview

Praxis Precision Medicines Q2 Earnings Call Highlights

Praxis Precision Medicines NASDAQ: PRAX said it is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and epileptic encephalopathies, or DEEs, as both new drug applications remain under FDA review.

news source

MarketBeat • Aug 7, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Praxis Precision Medicines Inc.

Open an M1 investment account to buy and sell Praxis Precision Medicines Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in PRAX on M1